An International, Randomized, Double-Blind, Parallel, Placebo-Controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (greater than or equal to 16 to 70 Years Old) Suffering From Localization-Related or Generalized Epilepsy.

Trial Profile

An International, Randomized, Double-Blind, Parallel, Placebo-Controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (greater than or equal to 16 to 70 Years Old) Suffering From Localization-Related or Generalized Epilepsy.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Adverse reactions; Registrational
  • Sponsors UCB
  • Most Recent Events

    • 21 Apr 2016 Pooled analysis of seizure and quality of life outcomes (n=1904) of 9 studies (NCT00175929, NCT00175825, NCT00490035, NCT00464269, NCT00504881, NCT01261325, NCT00175916, NCT00150800, and NCT01339559) were presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 27 Nov 2009 Results will be presented at the 63rd Annual Meeting of the American Epilepsy Society.
    • 16 Oct 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top